Results 191 to 200 of about 254,991 (312)

Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis. [PDF]

open access: yesFront Immunol
Yi JZ   +22 more
europepmc   +1 more source

Glucocorticoids

open access: yes, 2013
Glucocorticoids (GCs) are widely used for inflammatory and autoimmune diseases. Their mechanism of action is most commonly rooted in genomic effects that have both beneficial and adverse consequences. The purpose of this review is to discuss the potential complications and side effects that may occur with GC use. Many of these complications are related
openaire   +2 more sources

Genome‐Wide DNA Methylation Study Reveals Specific Signatures in the Affected Arterial Tissue of Patients With Giant Cell Arteritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Giant cell arteritis (GCA) is a large‐vessel vasculitis, potentially causing complications such as blindness and strokes. This study aims to gain insights into the pathogenesis of GCA by identifying specific DNA methylation signatures in the arterial tissue of patients with this vasculitis. Methods DNA methylation profiling was analyzed in 79
Gonzalo Borrego‐Yaniz   +18 more
wiley   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy